17534 Federal Register / Vol. 60, No. 66 / Thursday, April 6, 1995 / Notices

application that requests a hearing must

include a statement of why a written

presentation would not suffice in lieu of

a hearing, identifying specifically any

questions of fact that are in dispute and

summarizing the evidence that would

be presented at a hearing.

Comments regarding this application

must be received not later than May 1,

1995.

A. Federal Reserve Bank of Kansas

City (John E. Yorke, Senior Vice

President) 925 Grand Avenue, Kansas

City, Missouri 64198:

1. Buerge Bancshares, Inc., Joplin,

Missouri; to acquire 100 percent of the

voting shares of Peoples State Bank,

Claremore, Oklahoma.

Board of Governors of the Federal Reserve

System, March 31, 1995.

Barbara R. Lowrey,

Associate Secretary of the Board.

[FR Doc. 95–8407 Filed 4–5–95; 8:45 am]

BILLING CODE 6210–01–F

GENERAL SERVICES

ADMINISTRATION

Public Buildings Service; Proposed

Port of Entry, Located at Pacific

Highway, Blaine, Whatcom County,

WA; Notice of Availability for a Draft

Environmental Impact Statement

The general Services Administration

(GSA) hereby gives notice a Draft

Environmental Impact Statement (DEIS)

has been prepared in accordance with

the National Environmental Policy Act

(NEPA) of 1969, as amended. The DEIS

was prepared for the proposed

expansion of the Port of Entry located at

Pacific Highway, Blaine, Whatcom

County, Washington. The DEIS is being

made available March 31, 1995. GSA is

the lead Federal agency for the

preparation of the EIS. The DEIS

evaluates the proposed action, the noaction, and three (3) design alternatives.

Written comments should be as

specific as possible and may address the

adequacy of the EIS, the merits of the

alternatives discussed, the impacts

identified, and/or mitigation measures

recommended and be sent no later than

May 15, 1995 to GSA’s EIS

subconsultant, Berger/ABAM, at the

following address: 33301 Ninth Avenue

South, Federal Way, WA 98003.

Comments will also be accepted at a

public meeting to be held on April 19,

1995, at the Blaine Senior Center, 763

‘‘G’’ Street, Blaine, Washington 98230.

The meeting will be held from 5:30 p.m.

to 7:30 p.m.

Representatives of GSA and Berger/

ABAM will receive comments from

interested parties regarding the

proposed project, the environmental

analysis, and proposed mitigation

measures. All comments received will

be made a part of the administrative

record for the DEIS and will be

evaluated as part of the Final EIS review

process.

For further information contact Donna

M. Meyer, Regional Environmental

Program Officer, General Services

Administration, Public Buildings

Service (10PL), 400 15th Street SW.,

Auburn, Washington 98001–6599, or at

(206) 931–7675.

Dated: March 24, 1995.

L. Jay Pearson,

Regional Administrator (10A).

[FR Doc. 95–8414 Filed 4–5–95; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Office of the Secretary

Notice of Interest Rate on Overdue

Debts

Section 30.13 of the Department of

Health and Human Services’ claims

collection regulations (45 CFR Part 30)

provides that the Secretary shall charge

an annual rate of interest as fixed by the

Secretary of the Treasury after taking

into consideration private consumer

rates of interest prevailing on the date

that HHS becomes entitled to recovery.

The rate generally cannot be lower than

the Department of Treasury’s current

value of funds rate or the applicable rate

determined from the ‘‘Schedule of

Certified Interest Rates with Range of

Maturities.’’ This rate may be revised

quarterly by the Department of Health

and Human Services in the Federal

Register.

The Secretary of the Treasury has

certified a rate of 141⁄8 percent for the

quarter ended March 31, 1995. This

interest rate will remain in effect until

such time as the Secretary of the

Treasury notifies HHS of any change.

Dated: March 30, 1995.

George Strader,

Deputy Assistant Secretary, Finance.

[FR Doc. 95–8397 Filed 4–5–95; 8:45 am]

BILLING CODE 4150–04–M

Food and Drug Administration

[Docket No. 95N–0082]

Animal Drug Export; Deslorelin

Acetate Implant

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that Peptide Technology Ltd. has filed

an application requesting approval for

the export of the animal drug

OvuplantTM (deslorelin acetate) to

Canada.

ADDRESSES: Relevant information on

this application may be directed to the

Dockets Management Branch (HFA–

305), Food and Drug Administration,

rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, and to the contact

person identified below. Any future

inquiries concerning the export of

animal drugs under the Drug Export

Amendments Act of 1986 should also be

directed to the contact person.

FOR FURTHER INFORMATION CONTACT:

Gregory S. Gates, Center for Veterinary

Medicine (HFV–114), Food and Drug

Administration, 7500 Standish Pl.,

Rockville, MD 20855, 301–594–1617.

SUPPLEMENTARY INFORMATION: The drug

export provisions in section 802 of the

Federal Food, Drug, and Cosmetic Act

(the act) (21 U.S.C. 382) provide that

FDA may approve applications for the

export of drugs that are not currently

approved in the United States. Section

802(b)(3)(B) of the act sets forth the

requirements that must be met in an

application for approval. Section

802(b)(3)(C) of the act requires that the

agency review the application within 30

days of its filing to determine whether

the requirements of section 802(b)(3)(B)

have been satisfied. Section 802(b)(3)(A)

of the act requires that the agency

publish a notice in the Federal Register

within 10 days of the filing of an

application for export to facilitate public

participation in its review of the

application. To meet this requirement,

the agency is providing notice that

Peptide Technology Ltd., 4–10 Inman

Rd., Dee Why 2099, Australia, has filed

application number 8019 requesting

approval for the export of the animal

drug OvuplantTM (2.1 milligrams of

deslorelin per implant, as the acetate) to

Canada. The drug is a subcutaneous

implant providing sustained release of a

gonadotropin releasing hormone analog.

It is indicated for inducing ovulation in

the oestrus mare. The application was

received and filed in the Center for

Veterinary Medicine on March 20, 1995,